VEGF, flt-1, and KDR/flk-1 as Prognostic Indicators in Endometrial Carcinoma

Fine, Ben S.; Valente, Philip T.; Feinstein, Glen I.; Dey, Tammy D.

doi:10.1006/gyno.1999.5658

Cited by 64 publications

(46 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings confirm the expression of VEGF-A in endometrial cancer (Doldi et al, 1996;Guidi et al, 1996;Fujimoto et al, 1998;Fine et al, 2000), although in contrast to other published reports (Fujimoto et al, 1998;Fine et al, 2000), we did not demonstrate VEGF-A mRNA in benign specimens. This may be explained by the inclusion of both pre-and postmenopausal endometrium in other studies (Fujimoto et al, 1998).…”

Section: Discussionsupporting

confidence: 75%

Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer

et al. 2003

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 75%

Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer

et al. 2003

View full text Add to dashboard Cite

“…VEGF status was also an independent predictor of 5-and 10-year survival. In other studies, however, VEGF expression did not correlate with the incidence of metastases, recurrence, and survival [27][28][29]. The reason for the discrepancies between studies may lie in the varying expression pattern of VEGF in early versus late stage endometrial cancer.…”

Section: Discussionmentioning

confidence: 86%

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study

McMeekin

Sill

Benbrook

et al. 2007

Gynecologic Oncology

View full text Add to dashboard Cite

Objectives-A phase II trial was conducted to evaluate the anti-tumor activity and adverse effects of thalidomide in persistent or recurrent endometrial cancer refractory to cytotoxic chemotherapy, and to correlate angiogenesis biomarker expression with clinical outcome.Methods-Consenting patients were treated until progression or intolerable toxicity with an oral starting dose of 200 mg thalidomide/day that was to increase by 200 mg every 2 weeks to a target dose of 1000 mg/day. Vascular endothelial growth factor (VEGF), basic fibroblastic growth factor (bFGF), and soluble endothelial protein C receptor (sEPCR) were analyzed by ELISA in pre and post-treatment specimens.Results-Twenty-four of 27 patients enrolled in the study were eligible, of whom 2 reached the target dose, 8 progressed before achieving the target dose and 14 refused or had toxicity that prohibited escalation. Two patients (8.3%) remained progression-free ≥ 6 months. There were 3 (12.5%) with partial responses, 2 (8.3%) with stable disease, 15 (62.5%) with increasing disease, and 4 (16.7%) who were inevaluable for response. Median progression-free survival and overall survival Précis: Thalidomide has minimal activity in chemo-refractory endometrial cancer as judged by the ability to prolong progression-free survival greater than 6 months.Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

“…In endometrial carcinoma some studies on angiogenesis have been reported (Fine et al 2000;Fujiwaki et al 1999;Fujimoto et al 1998;. However, there are few studies that examine VEGF expression and its correlation with p53 expression using a large number of cases.…”

Section: Introductionmentioning

confidence: 94%

Immunohistochemical study on VEGF expression in endometrial carcinoma – comparison with p53 expression, angiogenesis, and tumor histologic grade

Fujisawa

Watanabe

Akaboshi

et al. 2001

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

VEGF, flt-1, and KDR/flk-1 as Prognostic Indicators in Endometrial Carcinoma

Cited by 64 publications

References 29 publications

Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer

Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer

A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: A Gynecologic Oncology Group study

Immunohistochemical study on VEGF expression in endometrial carcinoma – comparison with p53 expression, angiogenesis, and tumor histologic grade

Contact Info

Product

Resources

About